ClinConnect ClinConnect Logo
Search / Trial NCT05975541

Susceptibility to Infectious Diseases in Obesity

Launched by AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITA · Aug 2, 2023

Trial Information

Current as of November 10, 2025

Recruiting

Keywords

Obesity Adult Type 2 Diabetes Intestinal Microbiota Chronic Infections Immune System

ClinConnect Summary

This clinical trial is focused on understanding how the bacteria in our gut, known as gut microbiota, may influence the risk of infections in people who are obese or have type II diabetes. Researchers believe that changes in gut microbiota can affect the immune system, potentially making individuals with obesity and diabetes more susceptible to chronic infections. The main goal of the study is to see how gut bacteria differ between patients with chronic infections and those without, which could help in understanding the links between these conditions.

To participate in the study, eligible individuals must be between 18 and 65 years old, have obesity (a body mass index or BMI between 30 and 40), and have type II diabetes. They should also be willing to understand the study and be either experiencing chronic infections or not. It's important to note that certain individuals, such as those with severe health issues, recent infections, or who are pregnant, will not be able to take part. Participants can expect to undergo assessments related to their gut bacteria and health, contributing valuable information to help improve care for people with obesity and diabetes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age between 18-65 years
  • ability to understand the study protocol
  • obesity with BMI between 30-40 kg/m2
  • affects by type II diabetes
  • presence/absence of chronic infections
  • the possibility of equality in the two groups (matched for sex, age, and therapies)
  • Exclusion Criteria:
  • psychological conditions that reduced the ability the comprehension of the study protocol
  • subjects undergoing a diet-therapeutic regimen;
  • subjects with the possibility of developing diabetic foot in the successive months
  • patients with relapsing infections
  • pregnancy
  • bariatric surgery
  • oncological and hematological pathologies
  • Hypogonadism
  • severe immunodepression
  • vaccination in the last two weeks
  • Alcohol or drug abuse
  • antibiotic therapy

About Azienda Ospedaliero Universitaria Maggiore Della Carita

Azienda Ospedaliero Universitaria Maggiore della Carità is a leading academic hospital in Italy, renowned for its commitment to advancing healthcare through innovative clinical research and comprehensive patient care. With a focus on a wide range of medical specialties, the institution collaborates with various research entities to conduct rigorous clinical trials aimed at improving treatment outcomes and enhancing medical knowledge. Its state-of-the-art facilities and multidisciplinary approach ensure high-quality standards in research, fostering an environment conducive to scientific discovery and the development of new therapeutic strategies.

Locations

Novara, Italy

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported